Treatment of Human Immunodeficiency Virus 1-Infected Infants and Children with the Protease Inhibitor Nelfinavir Mesylate

An open-label study was conducted of nelfinavir mesylate, given with reverse transcriptase inhibitors to human immunodeficiency virus 1 (HIV-1)-infected infants and children 3 months to 13 years of age. Doses of nelfinavir mesylate of 20–30 mg/kg yielded drug exposures comparable to those seen in ad...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 1999-05, Vol.28 (5), p.1109-1118
Main Authors: Krogstad, Paul, Wiznia, Andrew, Luzuriaga, Katherine, Dankner, Wayne, Nielsen, Karin, Gersten, Merril, Kerr, Brad, Hendricks, Amy, Boczany, Barbara, Rosenberg, Martin, Jung, Denna, Spector, Stephen A., Bryson, Yvonne
Format: Article
Language:English
Subjects:
Adolescent
Anti-HIV Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
CD4 Lymphocyte Count - drug effects
Child
Child health services
Child, Preschool
Children
Clinical Articles
Dosage
Drug Therapy, Combination
Female
HIV 1
HIV Infections - drug therapy
HIV Protease Inhibitors - adverse effects
HIV Protease Inhibitors - pharmacokinetics
HIV Protease Inhibitors - therapeutic use
HIV-1 - drug effects
HIV-1 - isolation & purification
Human immunodeficiency virus 1
Human viral diseases
Humans
Infant
Infants
Infections
Infectious diseases
Lymphocytes
Male
Medical sciences
Nelfinavir - adverse effects
Nelfinavir - pharmacokinetics
Nelfinavir - therapeutic use
Pharmacokinetics
Pharmacology. Drug treatments
Reverse transcriptase inhibitors
Reverse Transcriptase Inhibitors - therapeutic use
RNA
RNA, Viral - blood
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An open-label study was conducted of nelfinavir mesylate, given with reverse transcriptase inhibitors to human immunodeficiency virus 1 (HIV-1)-infected infants and children 3 months to 13 years of age. Doses of nelfinavir mesylate of 20–30 mg/kg yielded drug exposures comparable to those seen in adults. The drug was well tolerated; mild diarrhea was the primary toxic effect observed. Seventy-one percent (39) of the 55 evaluable subjects had an initial decrease in plasma HIV-1 RNA, of at least 0.7 log10 copies/mL; suppression of plasma HIV-1 RNA levels to
ISSN:1058-4838
1537-6591
DOI:10.1086/514759